IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant: KIMCHY Yoav et al				§ 8	
				8 §	
Serial 1	No.:	10/616,301		§ 8	
Filed:		July 10, 2003		s § 8	Group Art Unit: 3737
For:		INGESTIBLE PILL		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Attorney Docket: 25854
Examir	ner:	CHAO ELMER M.		8 §	
Mail Stop Amendment Commissioner for Patents P.O. Box 1450					
		A 22313-1450			
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT					
Sir:					
Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited, other than U.S. Patents and U.S. patent applications. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56, 37 CFR 1.97 and 37 CFR 1.98. The Examiner is requested to make these citations of official record in this application.					
The undersigned states:					
A.:	NO C	ERTIFICATION OR FEE DUE			
This Information disclosure Statement is being filed within three months of filing a national application or entry of a national phase of an international application; or before the mailing date of a first Office action on the merits of the above-identified application. Accordingly, no fee or Certification is believed due. However, if a fee is due, authorization to deduct such fee from the Deposit Account 501407 of the undersigned is hereby provided.					
B.	CERT	IFICATION (if appropriate)			
That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or					
That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.					
C.	FEE (if appropriate)				
		Please charge the fee of \$180 set forth in 37 CFR 1.17(p)	to D	eposi	t Account 501407.
	n has b	nformation Disclosure Statement under 37 CFR 1.56 is not een made, that additional matter which is material to the expression or more of the citations listed constitutes prior art.			*
		Respect	fully	subn	nitted,
		/Martin	D. M	Ioyni	ihan/

Dated: August 31, 2009

Martin D. Moynihan Registration No. 40,338